What's Happening?
Onward Therapeutics has signed a worldwide license agreement with Institut du Cancer de Montpellier (ICM) to advance its onco-metabolism program, OT-S00X. This agreement follows a successful collaboration that identified promising compounds for cancer
treatment. The program aims to target tumor metabolism, offering a novel approach to overcoming cancer resistance. Preclinical studies have shown efficacy across multiple tumor types, with plans to nominate IND-enabling candidates next year.
Why It's Important?
The license agreement between Onward Therapeutics and ICM represents a significant step in developing innovative cancer therapies. By targeting tumor metabolism, OT-S00X could provide new treatment options for patients with resistant cancers, potentially improving outcomes and expanding therapeutic possibilities. This collaboration also highlights the importance of international partnerships in advancing translational science and driving innovation in oncology.
What's Next?
Onward Therapeutics plans to continue optimizing the OT-S00X program, with the goal of nominating IND-enabling candidates in the coming year. The company will leverage artificial intelligence to enhance the physico-chemical properties of its compounds, aiming to advance the program towards clinical trials. Ongoing collaboration with ICM and other stakeholders will be crucial in realizing the potential of this novel onco-metabolism strategy.
